MFY Stock Overview
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Mochida Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥18.50 |
| 52 Week High | JP¥24.80 |
| 52 Week Low | JP¥18.50 |
| Beta | 0.027 |
| 1 Month Change | -6.09% |
| 3 Month Change | -8.42% |
| 1 Year Change | -20.26% |
| 3 Year Change | -39.14% |
| 5 Year Change | -54.24% |
| Change since IPO | 2.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| MFY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -2.9% | -2.5% |
| 1Y | -20.3% | -31.3% | -0.4% |
Return vs Industry: MFY exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: MFY underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| MFY volatility | |
|---|---|
| MFY Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MFY has not had significant price volatility in the past 3 months.
Volatility Over Time: MFY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1913 | 1,529 | Naoyuki Mochida | www.mochida.co.jp |
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension.
Mochida Pharmaceutical Co., Ltd. Fundamentals Summary
| MFY fundamental statistics | |
|---|---|
| Market cap | €671.52m |
| Earnings (TTM) | €18.30m |
| Revenue (TTM) | €608.13m |
36.7x
P/E Ratio1.1x
P/S RatioIs MFY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MFY income statement (TTM) | |
|---|---|
| Revenue | JP¥100.09b |
| Cost of Revenue | JP¥48.80b |
| Gross Profit | JP¥51.29b |
| Other Expenses | JP¥48.27b |
| Earnings | JP¥3.01b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | 84.89 |
| Gross Margin | 51.24% |
| Net Profit Margin | 3.01% |
| Debt/Equity Ratio | 0% |
How did MFY perform over the long term?
See historical performance and comparison